Abstract:Background T2T is routine in RA, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was generated by Asia-Pacific Lupus Collaboration, and the preliminary validation demonstrated its attainment to be associated with improved outcomes in SLE. A SLEDAI-2K score lower than 4 is the main criteria for LLDAS. SSDM is an interactive mobile disease management application, including application systems for both the doctors and patients. The patients can perform self-assessment, including SLEDAI and medical records entry through the mobile application. The data is synchronized to the SSDM of authorized rheumatologists and stored in cloud database. Objectives To evaluate the patterns of T2T and related influential factors among SLE patients after applying SSDM in real world. Methods Patients were trained to master SSDM by rheumatologists in clinics. The first assessment for SLEDAI was performed as the baseline. Patients were required to perform repeated assessments after leaving the clinics. Results From July 2015 to Jan 2019, 1,090 SLE patients from 88 hospitals were followed up for more than 12 months through SSDM, and the results were summarized in Table 1. The ratio of T2T achievers was 52.84% (576/1,090) at the baseline and improved significantly to 68.35% (745/1,090) after a 12-month follow-up, p<0.01. Among T2T achievers at the baseline, 77.08% (444/576) maintained T2T, and 22.92% (132/576) relapsed. Of patients who didn’ t achieve T2Tat baseline, 58.56% (301/514) of the them achieve T2T after 12-month follow-up. The impact of the times of self-assessment for SLEDAI on T2T has been analyzed. The more frequent of the self-assessments being conducted by patients, the higher improvement of T2T rate will be. We performed linear regression analysis of variables in statistics and parameter estimation by least square method. The improvement of T2T rate(y) was positively correlated with times of self-assessment for SLEDAI(x) independently. The regression equation as “y = 0.0324x + 0.0226 R2 = 0.7717”, p<0.01. (Figure 1) Conclusion After proactive disease management via SSDM, the rate of T2T in SLE patients increased significantly. Patients with SLEDAI-2K≤4 score at baseline had a significantly higher retention rate. The patients who performed more self-assessments through SSDM had lower probability of relapse and higher rate of T2T maintaining and achievement. SSDM is a valuable tool for long term SLE follow-up through empowering patients.Table1: Baseline\Last follow-up Number % SLEDAI≤4 % SLEDAI≥5 % SLEDAI≤4 576 52.84% 444 77.08% 132 22.92% SLEDAI≥5 514 47.16% 301 58.56% 213 41.44% Total 1090 100% 745 68.35% 345 31.65%Figure 1 Disclosure of Interests None declared

Utilization of Drugs for Systemic Lupus Erythematosus in a Three-A Grade Hospital:Analysis of 76 Cases

Medication analysis of hospitalized patients with systemic lupus erythematosus in Beijing Hospital from 2008 to 2013

Comparison of Short Interval and Low Dose (SILD) with High Dose of Cyclophosphamide in the Susceptibility to Infection in SLE: a Multicentrereal-World Study

The analysis of the medication status and its relevance with lupus nephritis in systemic lupus erythematosus: a retrospective study of 252 patients

Analysis of Drugs for Patients with Rheumatoid Arthritis in a Certain 3A-Grade Hospital

Effect of Yangyin Jiedu Huoxue Recipe on Hormone Withdrawal and Disease Activity in Patients with Systemic Lupus Erythematosus

Use of Corticosteroid in Treating Patients with Systemic Lupus Erythematosus in Beijing

OP0250 INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET FOR SYSTEMIC LUPUS ERYTHEMATOSUS VIA EMPOWERING PATIENTS: A COHORT STUDY FROM CHINA BY SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.

Using linked electronic medical record-pharmacy data to examine lupus medication adherence: A retrospective cohort study

Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries

THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

Treatment patterns in patients with systemic lupus erythematosus in New Zealand

Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study

Causes And Factors Associated With Frequent Hospitalization In Chinese Patients With Systemic Lupus Erythematosus: An Ambispective Cohort Study

Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study

Evaluation of Pharmacological Therapy Effectiveness in Autoimmune Disease Management: A Focus on Systemic Lupus Erythematosus Patients

The Blood Concentration of Hydroxychloroquine and Its Safety in Patients with Systemic Lupus Erythematosus

Practice and Analysis of Clinical Pharmacists Personalized Medicine Scheme Design in Treatment of Lupus Nephritis Patients

Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.

[A Cross-Sectional Study on Application of Glucocorticoid in Systemic Lupus Erythematosus Patients].